Insulin-like growth factor 1 is a peptide hormone and growth mediator associated with growth hormone action. The liver supplies an important circulating source, and IGF-1 signalling helps coordinate growth of tissues including cartilage and bone. The regulatory pathway therefore connects a pituitary signal with growth-related responses in other tissues.[ref]
Anatomy and Physiology 2e by J. Gordon Betts and others. Section 17.3: Growth Hormone and Figure 17.10, liver-derived insulin-like growth factors and tissue growth
The motivating experiment was to look for a measurable activity in blood serum. A 1957 report by W. D. Salmon Jr. and William Daughaday examined a hormonally controlled serum factor through sulfate incorporation by cartilage in vitro.[ref]
A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro by W. D. Salmon Jr. and William Daughaday. Publication title and bibliographic record
In his later account, William Daughaday described cartilage culture and sulfate uptake as the readout that motivated the hypothesis of a serum mediator of growth hormone action.[ref]Growth hormone axis overview: somatomedin hypothesis by William Daughaday. Author retrospective, abstract: cartilage assay and the serum-mediator hypothesis
This was a functional assay: it detected what a serum preparation did to a tissue. Identifying the responsible molecules required further biochemical work. In 1978, E. Rinderknecht and R. E. Humbel reported structural homology between serum-derived IGF-I and proinsulin, providing a molecular basis for the insulin-like designation.[ref]
The historical progression connects three kinds of evidence: pituitary control, a tissue response to blood serum, and molecular identification of a protein. A serum bioactivity measurement and a measurement of one purified hormone answer different experimental questions.
Articles by others on the same topic
There are currently no matching articles.